Market Overview

Vetr Upgrades First Solar As Company Posts Strong Q3

Share:

The Vetr Crowd on Thursday upgraded its rating on First Solar, Inc. (NASDAQ: FSLR) from 4 stars (Buy), issued nine days ago, to 4.5 stars (Strong Buy). Crowd sentiment at the time of the upgrade was mostly positive, with 81 percent of Vetr user ratings bullish.

Vetr's upgrade comes just as First Solar reported its Q3 earnings, which showed the company beat both analyst sales expectations — $1.09 billion versus an estimated $866.8 million — and analyst EPS expectations — $1.95 versus an estimated $0.84. The company also raised its outlook on 2017.

First Solar finished Thursday's session at $47.92.

See how crowdsourced ratings could help you time the market.

Currently, the Vetr crowd's average price target on First Solar is up at $54.35, which is higher than the average analyst price target of $40.95. Less than 2 percent of Vetr users are holding $FSLR in their watch-lists.

Latest Ratings for FSLR

DateFirmActionFromTo
Apr 2019ReiteratesBuy
Apr 2019ReiteratesBuy
Jan 2019Initiates Coverage OnOverweight

View More Analyst Ratings for FSLR
View the Latest Analyst Ratings

Posted-In: VetrUpgrades Price Target Crowdsourcing Analyst Ratings General

 

Related Articles (FSLR)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
IINDoughertyAssumes34.0
PNRJefferiesInitiates Coverage On
YYUBSUpgrades
ROKUOppenheimerMaintains155.0
IPHIBank of AmericaMaintains80.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Square's October Rally Earns It Strong Buy From Vetr

A Look At Opiant Pharmaceuticals, The Stock That Skyrocketed On Trump's Opioid Declaration